gastrointestinal involvement (GI), nutritional status and medications may lead to Vit B12 deficiency. Objectives: We aimed to investigate the frequency of Vit B12 deficiency and its determinants in SSc patients. Methods: Sixty-two (90.3% female) SSc patients were enrolled in to the study. The nutritional status of patients was assessed with Malnutrition Universal Screening Tool (MUST). Serum Vitamin B12, homocysteine and Helicobacter Pylori Immunoglobulin G (H. Pylori IgG) levels were measured in all patients. Serum Vit B12 levels of patients were classified as; Low (<200 pg/ml), Borderline (200 -300 pg/ml) and Normal (>300 pg/ml). Serum homocysteine levels of patients were classified as; Elevated (>9 μmol/L) and hyperhomocysteinemia (>15 μmol/L). H. Pylori IgG antibody level >5 U/ml considered as positive. Serum Vit B12 level <200 pg/ml or being on Vit B12 replacement therapy was considered as B12 deficiency. Results: The mean age of the patients was 50.2 (12.5) years and mean disease duration was 12.0 (7.5) years. Forty-four (71.0%) patients were limited and 18 (29.0%) patients had diffuse SSc. The mean serum Vit B12 level of the patients was 323.6±291.5 pg/ml. Seventeen (27.4%) patients had normal, 23 (37.1%) patients had borderline and 22 (35.5%) patients had low serum Vit B12 level. Forty-four (71.0%) patients were considered as Vit B12 deficient; 22 had serum Vit B12 level <200 pg/ml (4 of these patients were on vitamin B12 replacement therapy), 22 were already on Vit B12 replacement therapy and Vit B12 level ≥200 pg/ml. The mean homocysteine levels were higher in the group with Vit B12 <200 pg/ml as compared to other groups (p=0.005). In the group with Vit B12 level <200 pg/ml, 33.3% (7/21) of the patients had hyperhomocysteinemia and 76.2% (16/21) had 'elevated homocysteine levels (Table) . Fifty-one (82.3%) patients had GIS involvement and 16 (25.8%) patients had medium-high risk MUST score. H. Pylori IgG antibody was positive in 40 (64.5%) patients. There were no statistically significant differences between the patients with and without Vit B12 deficiency regarding to age, mean disease duration, hemoglobin level, GI involvement, medium-high risk MUST score, H. Pylori IgG antibody positivity and other clinical features (p>0.05 for all).
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Homocysteine μmol/L, mean (SD) 9.1 (3. Background: Severe weakness of axial muscle leads to dropped head syndrome or camptocormia. The signification of these symptoms has not been studied in inflammatory myopathies (IM). Objectives: To assess the signification of dropped head syndrome and/or camptocormia in patients with IM. Methods: All practitioners of the French Myositis Network and the Club Rhumatisme et Inflammation (>1000 physicians) were invited to report their patients suffering from IM (myopathy with myositis specific autoantibody and/or typical muscle biopsy according to the ENMC criteria) with camptocormia and/or dropped head syndrome. These axial IM cases were included only if no other explanation of axial weakness was found. IM patients without axial involvement (non-axial IM group), were randomly selected from the participative centers, and included as control patients (ratio 1:2). Clinical, serological, muscle pathological features, management and outcomes were studied using a standardized form. Results: Twenty patients (sex ratio 2.6) with axial involvement (camptocormia: 60%, dropped head syndrome: 40%) were included. Background: Involvement of skin and musculoskeletal system in systemic sclerosis (SSc) leads to loss of function, disability and reduced quality of life. Data on efficacy of non-pharmacologic care in SSc is very limited due to variety in studied interventions/outcomes. Objectives: To address the limitations of existing studies, and evaluate the effect of a controlled, long-term (24-week intervention, 24-week follow-up), intensive (1h physiotherapy + 0.5h occupational therapy twice weekly, and home-exercise for 0.5h 5x weekly), tailored physiotherapy programme on function/impairment of hands/face, and quality of life/disability in cohorts with a substantial number of SSc patients. Methods: All patients fulfilled ACR/EULAR 2013 criteria, had skin involvement of hands/mouth, and were consecutively recruited from 2014 to 2016 at the Institute of Rheumatology in Prague. Both groups received educational materials and instructions for home exercise at baseline, however, only intervention group underwent the intensive physiotherapy programme. At months 0,3,6,12 all patients were assessed by a physician (physical examination, mRSS-Modified Rodnan's skin score, EUSTAR SSc activity score, Medsger SSc severity score), and a physiotherapist blinded to intervention [validated measurements (dFTPdelta finger to palm, inter-incisor/inter-lip distance, grip strength using Baseline dynamometer); tests (HAMIS-Hand Mobility In Scleroderma)], patients filled out patient reported outcomes/questionnaires (CHFS-Cochin Hand Function Scale, MHISS-Mouth Handicap In SSc Scale, HAQ, SHAQ, SF-36) and provided blood for routine laboratory analysis and biobanking. Normality of data was tested, inter-group analysis was performed with 2-way ANOVA, and intra-group analysis by Friedmann's test with Dunn's post hoc test. Results: 25 SSc patients (22 female/3 male, 14 limited cutaneous (lc)SSc/11 diffuse cutaneous (dc)SSc, median of age 54.0 and disease duration 7.0 years, mRSS 12) were recruited into the intervention group (IG) and 29 patients into the control group (CG) (25 female/4 male, 16 lcSSc/13 dcSSc, median of age 49.0 and disease duration 5.0 years, mRSS 11). Compared to observed statistically significant deterioration in CG over the period of m0-m6, we found statistically significant improvement in dFTP, grip strength, HAMIS, inter-incisor and inter-lip distance (Table 1) . Only numerical improvement in IG compared to numerical deterioration in CG, which have not reached statistical significance, were observed in patient reported outcomes (CHFS, MHISS, HAQ, SHAQ, SF-36). Conclusions: Our physiotherapy program not only prevented the natural course of progressive deterioration of function of hands/mouth (observed in the control group), but led to a significant improvement in monitored parameters, which was clinically meaningful in a substantial proportion of patients. Background: Polymyositis (PM) and Dermatomyositis (DM) are systemic inflammatory diseases affecting skeletal muscles and other organs, particularly hypopharynx and the upper tract of the esophagus, causing motility dysfunction. The current treatment for PM and DM relies on steroids and immunosuppressants, but esophageal involvement is often refractory to standard therapies. Objectives: To assess the efficacy and safety of intravenous immunoglobulins (Ig-iv) as therapy of refractory dysphagia (1) in patients affected with PM/DM who have received conventional treatments for at least three months. These are the extended data of a previous abstract entitled "Improvement of refractory dysphagia in patients with idiopathic inflammatory myopathies receiving immunoglobulin intravenous therapy" accepted to EULAR 2015 Congress. Methods: We enrolled 17 patients (15 F), 8 with DM, 9 with PM according to Bohan and Peter criteria, treated with prednisone (mean dose 20 mg/day) ± Methotrexate (15 mg/wk) or Azathioprine (100 mg/day) for at least 3 months, without improvement of dysphagia. All patients received one infusion of Ig at a standard dose (2 g/kg in a day) every two months for 3 cycles. In all patients, at entry and before each infusion, creatine kinase (CK) levels and Manual Muscle strength Test on 12 muscle groups (MMT12) were evaluated. Dysphagia assessment included: Eating Assessment Tool (EAT) impaired for score ≥3; Three-oz Swallow Test (3oST) and fibrolaryngoscopy (FEES) for pharyngeal muscle propulsion and stasis of liquid/solid bolus detection. Student T-test and Chi-square test were used to compare baseline and follow-up data. Results: At entry, all patients had an EAT score ≥3 with a mean score of 16.2±9, 3 patients presented a 3oST for solid (STPNS) impaired, and only 1 patient also for liquid (STPNL). CK levels were slightly increased (474±720 UI/L), and MMT12 score was 4.45±0.35. Following Ig-iv therapy we observed a significant improvement of EAT score after the first dose (9±8, p=0.006) with a further reduction after the second dose (7.4±8, p=0.007) and stability after the third one (7.6±8, p=0.008). An improvement of pharyngeal muscle propulsion, with a significant resolution of solid stasis and a partial resolution of liquid stasis were observed. In addition, MMT12 score progressively improved after each dose, increasing at 4.86±0.16 after the third dose (p=0.001). Noteworthy, after the third Ig-iv dose, three patients stopped the steroid and the remaining 12 were treated with a significant lower dose of 5 mg/day of prednisone (p=0.04). Conclusions: According to literature, our findings provided evidence that Ig-iv induced a meaningful improvement of dysphagia, also having a steroid-sparing effect. An improvement of muscle strength was also detected. Although further studies of larger cohort of patients and a longer follow-up time are needed, our findings corroborate the utility of Ig-iv in the treatment of more resistant idiopathic inflammatory myositis related dysphagia. 
